• Mount Sinai researcher explores keloid response to Dupixent

    9 monthes ago - By Healio

    Preliminary findings from Emma Guttman-Yassky, MD, PhD, and colleagues demonstrate a novel use of dupilumab for managing chronic keloids with reductions in skin fibrosis and keloidal scarring, which may suggest a potential underlying Th2 pathogenesis in keloid formation.
    “This is really a paradigm change because when you think of keloids, people think they are an abnormal fibroblast growth, an abnormal wound healing. No one thinks it is an inflammatory condition. That's completely a game changer,” Guttman-Yassky, of the department of dermatology and laboratory of inflammatory
    Read more ...